

Fukuda Denshi USA Announces Availability of Senszime's Next-Generation TetraGraph® Neuromuscular Monitoring System

Advanced quantitative EMG monitoring solutions from Senszime are now available through Fukuda Denshi USA to support safer anesthesia care.

REDMOND, WA, UNITED STATES, June 1, 2026 /EINPresswire.com/ -- [Fukuda Denshi](#) USA, Inc.

“

Our partnership with Senszime represents an important step forward in expanding Fukuda Denshi's perioperative monitoring capabilities with advanced quantitative neuromuscular monitoring technology.”

Justin Criddle, Vice President of Sales, Fukuda Denshi USA

today announced the availability of [Senzime's](#) Next-Generation TetraGraph® Neuromuscular Monitoring System in the United States, expanding access to advanced quantitative electromyography (EMG)-based neuromuscular monitoring solutions for anesthesia providers and hospitals.

Designed to support safer, more precise perioperative care, the Next-Generation TetraGraph® system delivers real-time quantitative monitoring of neuromuscular function using advanced EMG technology. The system supports Train-of-Four (TOF), Post-Tetanic Count (PTC), and Single Twitch (ST) monitoring, helping clinicians optimize

neuromuscular blocking agent dosing, support assessment of intubation readiness, and guide timely reversal and recovery.

Featuring Senszime's proprietary Level-of-Block Gauge™ and TetraGraph® Adaptive Intelligence™ technology, the system provides intuitive visualization, intelligent workflow support, and advanced signal optimization to improve clinical confidence throughout the perioperative continuum. Its portable, clinician-focused design also supports seamless integration into dynamic operating room environments.

Through this collaboration, Fukuda Denshi USA and Senszime aim to broaden access to advanced quantitative neuromuscular monitoring solutions while supporting hospitals through existing purchasing pathways, clinical education, and customer support resources.

“Our partnership with Senszime represents an important step forward in expanding Fukuda

Denshi's perioperative monitoring capabilities with advanced quantitative neuromuscular monitoring technology. By bringing the Next-Generation TetraGraph® system to clinicians and hospitals, we are reinforcing our shared commitment to enhancing patient safety, supporting evidence-based anesthesia practices, and delivering smarter monitoring solutions across the continuum of care."

— Justin Criddle, Vice President of Sales, Fukuda Denshi USA

"This collaboration with Fukuda Denshi USA reflects our shared commitment to advancing safer, more objective neuromuscular monitoring in anesthesia care. By expanding access to Next-Generation TetraGraph® technology, we are helping clinicians move beyond subjective assessment with EMG-based quantitative data, intuitive visualization, and workflow-support features designed for today's operating room."

— Michael Noble, Chief Marketing Officer, Senzime

The availability of the Next-Generation TetraGraph® system further expands Fukuda Denshi USA's anesthesia and perioperative monitoring portfolio, supporting healthcare providers with innovative technologies designed to enhance patient safety and workflow efficiency.

For more information, please visit:

<https://fukudaamerica.com/products/senzime-next-generation-tetragraph/>



Senzime Nex-Gen TetraGraph

About Fukuda Denshi USA, Inc.

Fukuda Denshi USA, Inc. provides advanced patient monitoring and diagnostic solutions designed to support clinicians across a wide range of healthcare environments. Through innovative technologies and dedicated customer support, Fukuda Denshi USA is committed to improving patient care and clinical workflow efficiency.

About Senzime

Senzime is a leading medical device company developing and marketing precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. Established in 1999 and headquartered in Uppsala, Sweden, Senzime's mission is to revolutionize perioperative care — smart and simple. Its TetraGraph® neuromuscular monitoring system is powered by advanced EMG technology to help clinicians worldwide optimize

neuromuscular blocking agent use and improve patient safety.

Customer Service

Fukuda Denshi USA, Inc.

+1 800-365-6668

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/915810779>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.